Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605758 · ClinicalTrials.gov registry record · Phase 3
Treatment of Strongyloides Infection
A Phase 3 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT03605758 is a Phase 3 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 51 participants.
The verdict
NCT03605758, a Phase 3 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.
Interventions
- DRUG Ivermectin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605758
The ClinicalTrials.gov registry entry for NCT03605758 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ivermectin is the first listed.
NCT03605758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605758 about?
NCT03605758 is a clinical study titled "Treatment of Strongyloides Infection". The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.
What is the current status of trial NCT03605758?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2012-05. Estimated completion is 2015-02-05.
What interventions are being tested in trial NCT03605758?
The interventions under investigation include: Ivermectin (DRUG).
Who is sponsoring clinical trial NCT03605758?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.